ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Program Announcements

July 25, 1986

NIH Consensus Conference Concludes That MRI In “Unusually Rewarding,” Calls For More Studies

November 6, 1987

NCI Intramural Programs: Clinical Trials Support System Need Attention, report Advises DCS

December 19, 1997

NI Consortium for cancer Genetics; Working Group to Meet

March 29, 1996

NCI Agrees To Offer New Screening RFP In The Future

May 28, 1976

Oncology Groups Oppose Proposed Cuts In Medicare Payments For Cancer Drugs

October 11, 2002